Pfizer Expands Breast Cancer Drug Reach with New FDA Nod for Metastatic Disease

The U.S. Food and Drug Administration (FDA) on Wednesday approved Pfizer Inc.’s (NYSE:PFE) TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab. This regimen serves as a maintenance therapy for adults battling unresectable locally advanced or metastatic HER2-positive breast cancer following their initial induction treatment. Read Also: Florida Attorney General Sues Pfizer for 'Misleading' COVID-19 Vaccine Safety Claims Promising Clinical Trial Outcomes This regulatory decision stems from the robust HER2CLIMB-05 Phase 3 trial. Patients receiving the TUKYSA combination experienced a 35.9% reduction in the risk of disease progression or death compared to those taking a placebo alongside trastuzumab and pertuzumab. The median progression-free survival reached 24.9 months for the TUKYSA arm, outperforming the 16.3 months observed in the placebo group. This provides patients with an additional 8.6 months of life without their cancer advancing. Expanding Front-Line Treatment Options TUKYSA already holds a Category 1 designation from the National Comprehensive Cancer Network as a second-line or later therapy for HER2-positive metastatic breast cancer in the U.S. This new approval elevates the drug to the front-line setting. It provides a valuable chemotherapy-free maintenance alternative, helping physicians tailor individual treatment strategies while successfully delaying disease progression. Technical Read Pfizer has a constructive longer-term setup, with its price above the 20-, 50-, 100-, and 200-day averages. The 20-day SMA is above the 50-day SMA, while the price sits about 6% above the 200-day SMA, showing an upward trend that still has room to strengthen. RSI is 56.19, a neutral reading that points to steady but not overheated momentum. Pfizer, Inc. Common Stock’s stock can still move higher without immediately facing the pressure that often follows an overbought reading, though momentum is not yet especially strong. MACD is below its signal line, indicating bearish pressure in the shorter-term momentum picture. Traders should watch for a bullish crossover as confirmation that the broader uptrend is regaining force, while continued weakness would suggest consolidation may persist. Support is near $24.00, while resistance is around $29.00. A clear move above resistance would support a continuation toward new highs, while a break below support would signal a deeper trend reversal and weaken the longer-term setup. The golden cross in September, when the 50-day SMA moved above the 200-day SMA, supports the bullish longer-term trend. Pfizer, Inc. Common Stock’s stock remains above both averages, but traders should watch whether that separation widens or begins to narrow. Pfizer, Inc. Common Stock’s stock is up 2.34% over the past 12 months, indicating a modest longer-term advance rather than a powerful breakout trend. With the stock at 78.5% of its 52-week range and close to the $29.21 high, a sustained move through resistance would be needed to turn that gradual gain into stronger upside momentum. The recent swing high and 52-week high occurred on September 2 after Pfizer, Inc. Common Stock’s stock broke above resistance on September 1, but the current MACD reading shows that follow-through has not been fully confirmed. The key trading question is whether price can reclaim strong momentum near the upper end of its range without falling back toward its moving-average support zone. PFE Price Action: Pfizer shares were up 1.83% at $28.00 at the time of publication on Wednesday, according to Benzinga Pro data. Read Also: Safe Pro Sees Revenue Exploding 2,300% as Defense Contracts Ramp Up Image via Shutterstock